Table 3.
Highlighted Metabolites significantly decreased with an Increase in 25(OH)D
| Metabolite | P-value | Bonferroni corrected P-value | −log10p | β Coef. | Super Pathway | Sub Pathway |
|---|---|---|---|---|---|---|
| Malonylcarnitine (C3-DC) | 6.84 E-06 | 3.95 E-03 | 5.16 | −0.0038 | Lipid | Acylcarnitines |
| 2-methylmalonylcarnitine (C4-DC) | 3.40 E-06 | 1.97 E-03 | 5.47 | −0.0050 | Lipid | Acylcarnitines |
| Succinylcarnitine (C4-DC) | 7.05 E-05 | 4.07 E-02 | 4.15 | −0.0034 | Lipid | Acylcarnitines |
| 3-methyladipoylcarnitine (C7-DC) | 1.05 E-05 | 6.04 E-03 | 4.98 | −0.0047 | Lipid | Acylcarnitines |
| Suberoylcarnitine (C8-DC) | 8.64 E-08 | 5.00 E-05 | 7.06 | −0.0063 | Lipid | Acylcarnitines |
| Octadecenedioylcarnitine (C18:1-DC)* | 2.07 E-07 | 1.20 E-04 | 6.68 | −0.0067 | Lipid | Acylcarnitiness |
| Octadecanedioylcarnitine (C18-DC)* | 4.72 E-05 | 2.73 E-02 | 4.33 | −0.0042 | Lipid | Acylcarnitines |
| 1-oleoyl-2-linoleoyl-GPE (18:1/18:2)* | 3.35 E-07 | 1.94 E-04 | 6.47 | −0.0042 | Lipid | Phosphatidylethanolamine |
| 1-stearoyl-2-oleoyl-GPE (18:0/18:1) | 9.63 E-07 | 5.57 E-04 | 6.02 | −0.0043 | Lipid | Phosphatidylethanolamine |
| 1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6)* | 1.00 E-11 | 5.78 E-09 | 11.00 | −0.0059 | Lipid | Phosphatidylethanolamine |
| 1-stearoyl-2-linoleoyl-GPE (18:0/18:2)* | 1.15 E-05 | 6.65 E-03 | 4.94 | −0.0034 | Lipid | Phosphatidylethanolamine |
| 1-oleoyl-2-arachidonoyl-GPE (18:1/20:4)* | 1.14 E-06 | 6.58 E-04 | 5.94 | −0.0036 | Lipid | Phosphatidylethanolamine |
| 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) | 4.32 E-06 | 2.50 E-03 | 5.36 | −0.0038 | Lipid | Phosphatidylethanolamine |
| 1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6)* | 1.52 E-07 | 8.76 E-05 | 6.82 | −0.0038 | Lipid | Phosphatidylethanolamine |
| 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) | 1.76 E-07 | 1.02 E-04 | 6.75 | −0.0043 | Lipid | Phosphatidylethanolamine |
| Indolelactate | 5.77 E-05 | 3.34 E-02 | 4.24 | −0.0035 | Amino Acid | Tryptophan Metabolism |
| Kynurenate | 1.32 E-05 | 7.62 E-03 | 4.88 | −0.0057 | Amino Acid | Tryptophan Metabolism |
| N-acetyltryptophan | 1.90 E-08 | 1.10 E-05 | 7.72 | −0.0177 | Amino Acid | Tryptophan Metabolism |
| 3-(4-hydroxyphenyl)lactate | 4.54 E-05 | 2.62 E-02 | 4.34 | −0.0037 | Amino Acid | Tyrosine Metabolism |
| N-acetyltyrosine | 3.85 E-05 | 2.22 E-02 | 4.41 | −0.0047 | Amino Acid | Tyrosine Metabolism |
| 3-methoxytyramine sulfate | 1.52 E-05 | 8.79 E-03 | 4.82 | −0.0049 | Amino Acid | Tyrosine Metabolism |
| Homovanillate | 1.23 E-06 | 7.09 E-04 | 5.91 | −0.0050 | Amino Acid | Tyrosine Metabolism |
| Vanillylmandelate | 1.12 E-06 | 6.46 E-04 | 5.95 | −0.0056 | Amino Acid | Tyrosine Metabolism |
| Homovanillate sulfate | 1.45 E-06 | 8.40 E-04 | 5.84 | −0.0066 | Amino Acid | Tyrosine Metabolism |
Note: Increase in 25(OH)D is defined as the absolute ng/ml increase in plasma 25(OH)D from baseline day 0 to day 3 following randomization.
indicates the metabolite has a recognized identification with predictive or externally acquired structure evidence. All other Metabolites have validated identification against a pure reference standard. GPC is glycerylphosphorylcholine; GPE is glycerophosphoethanolamine. For the Acylcarnitine sub pathway: a capital C is followed by the number of carbons within the fatty acyl group attached to the carnitine. A colon followed by a number is one or more unsaturated carbons in the acylcarnitine ester (i.e. C10:1 is a monounsaturated C10 acylcarnitine). DC following the carbon number is a dicarboxylic acylcarnitine. All significant mixed-effects associations have P-value < 8.65 × 10−5.